-$0.02 EPS Expected for Ampio Pharmaceuticals, Inc. (NYSE:AMPE) This Quarter

Analysts expect Ampio Pharmaceuticals, Inc. (NYSE:AMPE – Get Rating) to post ($0.02) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals also posted earnings per share of ($0.02) during the same quarter last year. The company is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Ampio Pharmaceuticals will report full-year earnings of ($0.09) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($0.08) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Ampio Pharmaceuticals.

Separately, StockNews.com initiated coverage on shares of Ampio Pharmaceuticals in a report on Saturday. They set a “sell” rating on the stock.

Shares of NYSE AMPE traded down $0.03 during trading on Wednesday, hitting $0.37. The company had a trading volume of 67,411 shares, compared to its average volume of 1,763,526. Ampio Pharmaceuticals has a 12 month low of $0.38 and a 12 month high of $2.01. The company has a 50 day simple moving average of $0.46.

Ampio Pharmaceuticals Company Profile (Get Rating)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

Recommended Stories